- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent...
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of...
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative...
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi...
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”...
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic...
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive...
DEER PARK, Ill., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”...
DEER PARK, Ill., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or the “Company”) (Nasdaq:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.